---
title: "Transitioning to RBQM: Insights from Tufts CSDD Roundtables | CluePoints"
description: Understand the cultural, operational, and technological shifts needed to move from rigid, checklist-driven processes to a proportionate, risk-based approach.
---
### Transitioning to Risk-Based Clinical Trial Management: Insights from Tufts CSDD and CluePoints Roundtables
%20White%20Paper.png?width=532&height=278&name=ICH%20E6(R3)%20White%20Paper.png)
**ICH E6(R3): How industry & regulators are making the transition to Risk-Based Clinical Trial Management**
*Download the new Tufts CSDD White Paper for themes and insights from roundtable discussions between industry executives and representatives from global regulatory agencies.*
The final ICH E6 R3 guidelines are encouraging clinical research stakeholders to move away from checklist-driven compliance toward risk-based, fit-for-purpose processes that leverage proportional risk, digital technologies, and site and participant-centric practices. This white paper from the Tufts Center for the Study of Drug Development (CSDD) — developed in collaboration with CluePoints — summarizes the outcomes of two in-depth roundtable discussions between senior R&D leaders and regulators from FDA, EMA, and MHRA.
Specifically, the white paper examines how organizations are approaching and navigating the transition, and the challenges they are encountering/expect to encounter. Key themes and insights include:
- **Embedding proportionality and QbD from the outset **
See how Sponsors are moving away from rigid protocols and instead designing studies that focus on what is critical to quality, feasibility, and participant safety.
- **Strengthening accountability and collaboration across functions**
Understand how ICH E6(R3) clarifies responsibilities for Sponsors, CROs, investigators, and vendors, ensuring accountability aligns with operational control.
- **Building training and capabilities needed to adopt R3**
Explore how global training initiatives, regulatory guidance, and internal upskilling efforts are preparing organizations for consistent, modern interpretation of the guideline.
- **Closing infrastructure and technology gaps**
Learn what’s needed to transition from legacy, paper-heavy workflows to integrated platforms that support centralized monitoring, data governance, and real-time oversight.
- **Accelerating cultural change for sustainable RBQM maturity**
Discover why shifting mindsets, toward transparency, critical thinking, and cross-functional integration, is as important as updating systems and processes.
**Download the white paper today.**
### **Access the Full ICH E6(R3) Insights Report**
****[](https://www.facebook.com/CluePoints/) [](https://www.linkedin.com/company/cluepoints/) [](https://twitter.com/cluepoints?lang=en)****
****### First Pain Point
This should be the biggest pain your clients have as it relates to your service. What are you doing for them?
[Read More](https://www.webcanopystudio.com)
### First Pain Point
This should be the biggest pain your clients have as it relates to your service. What are you doing for them?
[Read More](https://www.webcanopystudio.com)
### First Pain Point
This should be the biggest pain your clients have as it relates to your service. What are you doing for them?
[Read More](https://www.webcanopystudio.com)
© 2026 CluePoints Inc.****
```json
{
"@context" : "https://schema.org",
"@type" : "Article",
"author" : [ {
"@type" : "Person",
"affiliation" : "Tufts Center for the Study of Drug Development - Tufts University School of Medicine",
"jobTitle" : "Senior Consultant",
"name" : "Maria Florez",
"url" : "https://csdd.tufts.edu/people/maria-florez"
}, {
"@type" : "Person",
"affiliation" : "Tufts Center for the Study of Drug Development - Tufts University School of Medicine",
"jobTitle" : "Data Scientist",
"name" : "Abigail Dirks",
"url" : "https://csdd.tufts.edu/people/abigail-dirks"
}, {
"@type" : "Person",
"affiliation" : "Tufts Center for the Study of Drug Development - Tufts University School of Medicine",
"jobTitle" : "Executive Director and Professor",
"name" : "Kenneth Getz",
"url" : "https://csdd.tufts.edu/people/kenneth-getz"
}, {
"@type" : "Person",
"affiliation" : "CluePoints Inc",
"jobTitle" : "Chief Strategy Officer",
"name" : "Richard Young",
"url" : "https://www.linkedin.com/in/richard-young-96029a4/"
}, {
"@type" : "Person",
"affiliation" : "CluePoints Inc",
"jobTitle" : "Vice President, Strategic Consulting",
"name" : "Sas Maheswaran",
"url" : "https://www.linkedin.com/in/sas-maheswaran-560138115/"
}, {
"@type" : "Person",
"affiliation" : "CluePoints Inc",
"jobTitle" : "Vice President, Strategic Consulting",
"name" : "Ken McFarlane",
"url" : "https://www.linkedin.com/in/ken-mcfarlane-1765aa10/"
}, {
"@type" : "Person",
"affiliation" : "CluePoints Inc",
"jobTitle" : "Event Manager",
"name" : "Stephenie Wright",
"url" : "https://www.linkedin.com/in/stephenie-wright4/"
}, {
"@type" : "Person",
"affiliation" : "CluePoints",
"jobTitle" : "Event Manager",
"name" : "Carly Ivanov",
"url" : "https://www.linkedin.com/in/carly-ivanov-69b38979/"
}, {
"@type" : "Person",
"affiliation" : "Novartis",
"jobTitle" : "GCP Compliance Head EMEA",
"name" : "Paula Babarovic"
}, {
"@type" : "Person",
"affiliation" : "AstraZeneca",
"jobTitle" : "Executive Director, Clinical Operations",
"name" : "Kathryn Bohannon"
}, {
"@type" : "Person",
"affiliation" : "Syneos Health",
"jobTitle" : "President, Clinical Development",
"name" : "Paula Bain"
}, {
"@type" : "Person",
"affiliation" : "Gilead",
"jobTitle" : "Head of RBQM",
"name" : "Joanne Benedict"
}, {
"@type" : "Person",
"affiliation" : "Syneos Health Consulting",
"jobTitle" : "Business Consultant, R&D Advisory",
"name" : "Leonie Christianson"
}, {
"@type" : "Person",
"affiliation" : "Syneos Health Consulting",
"jobTitle" : "Director",
"name" : "Janet Fernihough"
}, {
"@type" : "Person",
"affiliation" : "Pfizer",
"jobTitle" : "Director, Senior Asset Lead",
"name" : "Ashley Howard"
}, {
"@type" : "Person",
"affiliation" : "PPD",
"jobTitle" : "Executive Director",
"name" : "Robert King"
}, {
"@type" : "Person",
"affiliation" : "Astellas",
"jobTitle" : "Head of Global Data Management",
"name" : "Lesley Lardino"
}, {
"@type" : "Person",
"affiliation" : "Novo Nordisk",
"jobTitle" : "Vice President, RBQM",
"name" : "Bo Maach-Moller"
}, {
"@type" : "Person",
"affiliation" : "Thermo Fisher Scientific - PPD",
"jobTitle" : "Senior Director, Regulatory Affairs",
"name" : "James McCormick"
}, {
"@type" : "Person",
"affiliation" : "Parexel",
"jobTitle" : "Senior Director, Global Clinical Operations, RBQM",
"name" : "Cris McDavid"
}, {
"@type" : "Person",
"affiliation" : "UBC",
"jobTitle" : "Executive Director, Evidence Development Operations",
"name" : "Eileen Moran"
}, {
"@type" : "Person",
"affiliation" : "UCB",
"jobTitle" : "Head Clinical Data Management",
"name" : "Noleen Turner"
}, {
"@type" : "Person",
"affiliation" : "Alnylam",
"jobTitle" : "Associate Director, Clinical Risk and Analytics",
"name" : "Miguel Valenzuela"
}, {
"@type" : "Person",
"affiliation" : "Bayer",
"jobTitle" : "Head of Clinical Trial Management Services",
"name" : "Emma Earl"
} ],
"datePublished" : "2025-12-15",
"description" : "Discover how global regulators, industry leaders, and clinical research organizations are reshaping clinical trial management in preparation for ICH E6(R3). Learn how proportionality, critical-to-quality thinking, and early Quality by Design (QbD) are driving a more modern, sustainable approach to trial oversight.
Clinical development is at a turning point. As the industry moves away from checklist-driven compliance toward risk-based, fit-for-purpose processes, many Sponsors face cultural, operational, and infrastructure challenges. In this new white paper from the Tufts Center for the Study of Drug Development (CSDD), developed in collaboration with CluePoints, you’ll gain insights from two roundtables with more than 120 senior R&D leaders and regulators from FDA, EMA, and MHRA.
This report explores how organizations are navigating the transition, and what it takes to embed risk-based thinking across teams, systems, and study operations.",
"headline" : "Transitioning to Risk-Based Clinical Trial Management: Insights from Tufts CSDD and CluePoints Roundtables",
"image" : "https://lp.cluepoints.com/hs-fs/hubfs/ICH%20E6(R3)%20White%20Paper.png",
"mainEntityOfPage" : {
"@id" : "https://lp.cluepoints.com/transitioning-to-risk-based-clinical-trial-management-insights-from-tufts-csdd-roundtables-cluepoints",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://lp.cluepoints.com/hs-fs/hubfs/clue_points_cmyk.jpg"
},
"name" : "CluePoints Inc."
}
}
```